ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Below 200-Day Moving Average of $2.00

ProQR Therapeutics (NASDAQ:PRQR) crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $2.00 and traded as low as $1.86. ProQR Therapeutics shares last traded at $1.89, with a volume of 48,021 shares traded.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on PRQR shares. Citigroup lifted their price target on ProQR Therapeutics from $1.80 to $2.00 and gave the company a “buy” rating in a report on Thursday, April 18th. Chardan Capital restated a “buy” rating and issued a $2.50 target price on shares of ProQR Therapeutics in a research report on Friday, May 10th. HC Wainwright reiterated a “buy” rating and set a $5.00 price target on shares of ProQR Therapeutics in a research report on Friday, May 10th. Finally, StockNews.com raised ProQR Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, June 29th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $3.38.

ProQR Therapeutics Price Performance

The firm has a market capitalization of $152.96 million, a P/E ratio of -5.08 and a beta of 0.42. The firm’s fifty day moving average price is $1.79 and its 200-day moving average price is $2.00.

ProQR Therapeutics (NASDAQ:PRQR) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02. ProQR Therapeutics had a negative return on equity of 61.58% and a negative net margin of 260.75%. The firm had revenue of $4.83 million during the quarter, compared to analyst estimates of $3.31 million. Analysts expect that ProQR Therapeutics will post -0.37 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of PRQR. RFG Advisory LLC acquired a new stake in ProQR Therapeutics in the 1st quarter valued at about $73,000. BNP Paribas Financial Markets raised its holdings in shares of ProQR Therapeutics by 120.1% in the 1st quarter. BNP Paribas Financial Markets now owns 35,001 shares of the biopharmaceutical company’s stock worth $80,000 after purchasing an additional 19,100 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in ProQR Therapeutics during the first quarter valued at approximately $56,000. EP Wealth Advisors LLC bought a new stake in ProQR Therapeutics during the first quarter worth approximately $26,000. Finally, Ikarian Capital LLC grew its position in ProQR Therapeutics by 2.3% in the first quarter. Ikarian Capital LLC now owns 483,583 shares of the biopharmaceutical company’s stock worth $1,098,000 after buying an additional 10,958 shares during the last quarter. Institutional investors own 32.65% of the company’s stock.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).